Health Care [ 2/12 ] | Biotechnology [ 22/74 ]
NASDAQ | Common Stock
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 26 | -1.38 Increased by +58.43% | -0.89 Decreased by -55.00% |
| Feb 19, 26 | -2.57 Increased by +5.17% | -0.60 Decreased by -325.57% |
| Oct 29, 25 | -4.96 Decreased by -0.72% | -3.36 Decreased by -47.49% |
| Aug 5, 25 | -1.90 Increased by +73.24% | -3.63 Increased by +47.66% |
| May 5, 25 | -3.32 Increased by +55.01% | -6.28 Increased by +47.13% |
| Feb 26, 25 | -2.71 Increased by +52.29% | -4.12 Increased by +34.30% |
| Oct 31, 24 | -4.92 Increased by +7.87% | -6.91 Increased by +28.80% |
| Aug 7, 24 | -7.10 Decreased by -51.39% | -7.53 Increased by +5.71% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 311.34 M Increased by +126.84% | -94.39 M Decreased by -28.88% | Decreased by -30.32% Increased by +43.18% |
| Dec 31, 25 | 321.08 M Increased by +210.77% | -58.58 M Increased by +1.42% | Decreased by -18.24% Increased by +68.28% |
| Sep 30, 25 | 287.27 M Increased by +362.03% | -114.19 M Decreased by -6.76% | Decreased by -39.75% Increased by +76.89% |
| Jun 30, 25 | 212.80 M Increased by +1.35 K% | -42.28 M Increased by +72.18% | Decreased by -19.87% Increased by +98.09% |
| Mar 31, 25 | 137.25 M Increased by +N/A% | -73.24 M Increased by +50.36% | Decreased by -53.36% Decreased by N/A% |
| Dec 31, 24 | 103.32 M Increased by +13.32 K% | -59.42 M Increased by +47.04% | Decreased by -57.51% Increased by +99.61% |
| Sep 30, 24 | 62.17 M Increased by +N/A% | -106.96 M Decreased by -8.33% | Decreased by -172.04% Decreased by N/A% |
| Jun 30, 24 | 14.64 M Increased by +N/A% | -151.97 M Decreased by -77.12% | Decreased by -1.04 K% Decreased by N/A% |